伊布替尼联合利妥昔单抗治疗复发或难治性套细胞淋巴瘤的单臂II期临床试验四年随访
本文报告一项单中心、单臂、开放标签II期研究,评估伊布替尼联合利妥昔单抗治疗复发或难治性套细胞淋巴瘤的长期疗效与安全性。中位随访47个月,29例(58%)达完全缓解,中位无进展生存期43个月,中位总生存期未达。母细胞样形态、高危MCL国际预后指数评分和高Ki67%患者生存较差。
要点
- 中位随访47个月,29例(58%)达完全缓解,中位无进展生存期43个月。
- 18例(36%)死亡,其中14例为MCL相关死亡,中位总生存期未达。
- 母细胞样形态、高危MCL国际预后指数评分和高Ki67%与较差生存相关。
核心结论
- 伊布替尼联合利妥昔单抗可使部分复发或难治性套细胞淋巴瘤患者获得持久缓解,尤其是低Ki67%患者。
- 联合其他治疗与伊布替尼联合利妥昔单抗方案在复发或难治性套细胞淋巴瘤中的可能获益正在探索中。
研究设计与样本
- 单中心、单臂、开放标签、II期临床研究,评估伊布替尼联合利妥昔单抗治疗复发或难治性套细胞淋巴瘤。
- 中位随访时间47个月(范围1-52个月),中位治疗持续时间16个月(范围1-53个月),中位治疗周期数17(范围1-56)。
主要发现
- 29例患者(58%)达完全缓解,其中12例仍在研究中。
- 38例患者终止治疗,14例因疾病进展(其中2例转化)。
- 常见1-2级毒性为乏力、腹泻、恶心、关节痛和肌痛,无长期毒性。
- 中位无进展生存期43个月。
- 18例患者(36%)死亡,其中14例死亡与MCL相关;中位总生存期未达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib has shown significant activity in patients with relapsed or refractory mantle cell lymphoma (RR-MCL). We report the long-term outcome and safety profile of a single-centre, single arm, open-label, phase 2 study of RR-MCL treated with IR. Overall, the median follow-up time was 47 months (range 1-52 months), median duration on treatment was 16 months (range 1-53 months) and median number of treatment cycles was 17 (range 1-56). Twenty-nine patients (58%) achieved complete remission and of these, 12 patients continue on study. Thirty-eight patients discontinued treatment, 14 due to disease progression (2 transformed). Patients with blastoid morphology, high risk MCL International Prognostic Index score and high Ki67% had inferior survival. The commonest grade 1-2 toxicities were fatigue, diarrhoea, nausea, arthralgias and myalgias. None had long term toxicities. Median progression-free survival was 43 months. Eighteen patients (36%) died (14 deaths were MCL-related). The median overall survival has not been reached. Treatment with IR can provide durable remissions in a subset of patients with RR-MCL, especially those with low Ki67%. The possible benefit of adding other therapies in combination with IR in RR-MCL is under exploration.
引用
- Jain P, Romaguera J, Srour SA, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018. PMID: 29785709. doi:10.1111/bjh.15411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。